Recent clinical data indicates that the emergence of mutant drugresistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance mutation screens with erlotinib, lapatinib and CI-1033. Distinct mutation spectra were generated with each inhibitor and were reflective of their respective mechanisms of action. Lapatinib yielded the widest variety of mutations, whereas mutational variability was lower in the erlotinib and CI-1033 screens. Lapatinib was uniquely sensitive to mutations of residues located deep within the selectivity pocket, whereas mutation of either Gly 796 or Cys 797 resulted in a dramatic loss of CI-1033 potency. The clinically observed T790M mutation was common to all inhibitors, but occurred with varying frequencies. Importantly, the presence of C797S with T790M in the same EGFR allele conferred complete resistance to erlotinib, lapatinib and CI-1033. The combination of erlotinib and CI-1033 effectively reduced the number of drug-resistant clones, suggesting a possible clinical strategy to overcome drug resistance. Interestingly, our results also indicate that co-expression of ErbB2 (v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2) has an impact upon the EGFR resistance mutations obtained, suggesting that ErbB2 may play an active role in the acquisition of drug-resistant mutations.
INTRODUCTION
Clinical data have indicated that the use of targeted therapies to selectively inactivate an oncogenic kinase creates selective pressures that a tumour can overcome through the outgrowth of a drug-resistant population [1] . Mutations that confer resistance to targeted therapies have emerged as one of the common mechanisms for acquired secondary resistance [2, 3] . For example, BCR (breakpoint cluster region)-Abl mutations are speculated to be responsible for 50-90 % of CML (chronic myeloid leukaemia) relapses following imatinib treatment [2] . A similar mechanism of resistance through mutation can also occur in NSCLC (nonsmall-cell lung cancer) patients treated with EGFR inhibitors [3] . Approx. 50 % of relapsed patients acquire a gatekeeper mutation (T790M) within the EGFR kinase domain [3] that is structurally analogous to the T315I mutation commonly found in BCR-Abl. Thus far, gatekeeper mutants have proved particularly difficult to overcome in the clinic, presumably because many kinase inhibitors are designed to interact with the adjacent hydrophobic (selectivity) pocket. Interestingly, a family of irreversible inhibitors that form a covalent bond with residue Cys 797 within the EGFR kinase domain demonstrate significant preclinical potency towards EGFR T790M [4] [5] [6] . Consequently, examples of irreversible inhibitors such as EKB-569 [7] and HKI-272 [8] are now being evaluated in relapsed NSCLC patients.
Since resistance mutations appear to be a recurring clinical issue, we were particularly interested in exploring the structural relationships between kinase inhibitors and the point mutations that confer resistance to them. In the present study, we chose to examine EGFR [EGF (epidermal growth factor) receptor] as a model system, since there are multiple types of EGFR inhibitors available with distinct mechanisms of action. Erlotinib ( Figure 1 ) is a specific EGFR inhibitor that blocks activity through direct competition with ATP [9] . Lapatinib ( Figure 1 ) is a dual inhibitor of EGFR and ErbB2 (v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2) that binds in the ATP site. The crystal structure of lapatinib bound to EGFR revealed that it preferentially targets an inactive conformation of EGFR [10] . CI-1033 (PD 183805) ( Figure 1 ) is a pan-ErbB family inhibitor that forms a covalent bond with EGFR Cys 797 resulting in dramatically increased inhibitor potency [11] . Erlotinib, lapatinib and CI-1033 are of further interest, since they represent the three classes of inhibitors used to target ErbB family members in the clinic [12] [13] [14] .
To compare the mutation spectra obtained we performed in vitro resistance screens and identified a variety of novel EGFR resistance mutations. We confirmed that T790M was particularly important for erlotinib resistance, whereas the pattern of resistance obtained with lapatinib was reminiscent of that obtained with imatinib [15] , highlighting their similar conformational requirements. We also report that the potency of irreversible kinase inhibitors is significantly affected by mutation of residues involved in covalent attachment and that the presence of ErbB2 can influence the EGFR mutation spectrum induced by erlotinib. Finally, we combined two mutations to produce a form of EGFR that was completely insensitive to erlotinib, lapatinib and CI-1033, suggesting that this double mutant may be particularly difficult to treat if it arises in the clinic.
Abbreviations used: BCR, breakpoint cluster region; CML, chronic myeloid leukaemia; EGF, epidermal growth factor; EGFR, EGF receptor; ErbB2, v-erb-b2 erythroblastic leukaemia viral oncogene homologue 2; IL-3, interleukin 3; MTS, methanethiosulfonate; NSCLC, non-small-cell lung cancer. 1 Present address: Translational Anti-Angiogenesis Laboratory, School of Cancer and Imaging Sciences, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, U.K. 2 To whom correspondence should be addressed at the present address: Novartis Institutes for Biomedical Research, Cambridge, MA 02139, U.S.A. (email Andrew.Garner@novartis.com).
Figure 1 Chemical structures of ErbB family tyrosine kinase inhibitors
The reported selectivity profile compared with the ErbB family members is indicated in parentheses.
MATERIALS AND METHODS

Cell culture and generation of cell lines
Ba/F3 cells were cultured in RPMI 1640 medium (SigmaAldrich) supplemented with L-glutamine (2 mM), 10 % (v/v) fetal calf serum and 0.1 % (v/v) WEHI-3B-conditioned medium as a source of IL-3 (interleukin 3). Ba/F3 cells expressing Myc-tagged versions of EGFR, EGFR-L858R, ErbB2 and EGFR or EGFR-L858R resistance mutants were generated by retroviral infection. Viruses were produced using the Phoenix packaging cell line. Ba/F3 cells (1 × 10 6 ) were infected in the presence of 1.5 % WEHI-3B-conditioned medium and 8 μg/ml polybrene (SigmaAldrich). Infections were carried out at 1400 g for 45 min at 33
• C followed by overnight incubation at 37
• C. Cells expressing EGFR and ErbB2 proteins were selected in either 0.7 μg/ml puromycin (Sigma-Aldrich) or 300 μg/ml hygromycin (Invitrogen). When required, cells were switched to IL-3-free RPMI medium supplemented with either 20 ng/ml EGF (R&D Systems) or 10 ng/ml heregulin (R&D Systems). To generate Ba/F3 cells co-expressing EGFR and ErbB2, Ba/F3/ErbB2 cells were maintained in IL-3-free medium supplemented with 10 ng/ml heregulin. Cells were infected with EGFR-pBabe Puro and selected with 0.7 μg/ml puromycin and 300 μg/ml hygromycin.
Vector generation
EGFR-Myc and ErbB2-Myc were amplified from EGFR-MycpENTRY or ErbB2-Myc-pENTRY plasmids (kindly supplied by Dr D. Robinson, AstraZeneca, Macclesfield, U.K.) using PfuUltra hotstart PCR master mix (Stratagene) and standard amplification conditions. Forward primers contained an SnaBI restriction site (5 -GGGGTACGTAGCCACCATGCGACCCTCCGGGACGG-CCGGG-3 for EGFR and 5 -GGGGTACGTAGCCACCATGG-AGCTGGCGGCCTTGTGCCGC-3 for ErbB2). The reverse primers contained an EcoRI restriction site (5 -CGCGGAA-TTCCTACAGATCCTCTTCTGAGATGAG-3 for both EGFR and ErbB2). The reverse primer was designed to also incorporate an in-frame Myc tag at the 3 -end of EGFR and ErbB2. EGFR was cloned into the SnaBI and EcoRI sites of the pBabe Puro vector and ErbB2 was cloned into the SnaBI and EcoRI sites of the pBabe Hygro vector. Both pBabe vectors were generously donated by Dr Margaret Frame (The Beatson Institute for Cancer research, Glasgow, U.K.).
Library construction
The EGFR fragment (residues 613-1036) was randomly mutated using the EzClone domain mutagenesis kit (Stratagene) as recommended by the manufacturer. Forward (5 -AGACGCCGG-CCATGTGTGCCACC-3 ) and reverse (5 -CAGAGAGCTCAG-GAGGGGAGTCC-3 ) primers were used for the error-prone PCR. The EzClone reaction (50 μl) was performed using 50 ng of EGFR-pBabe Puro plasmid and 500 ng of mutated PCR product. Non-mutated plasmid was digested with DpnI (New England Biolabs). The library was transformed into maximum-efficiency DH5α cells (Invitrogen) and plasmid DNA was extracted using Qiagen extraction kits.
Resistance mutation screens
Ba/F3 or Ba/F3/ErbB2 cells (1 × 10 6 ) were infected with the EGFR mutation library to achieve 30-40 % infection efficiency in order to avoid multiple proviral integrations in each cell. Infected cells were washed twice with PBS before being resuspended in RPMI 1640 medium supplemented with 10 % (v/v) fetal calf serum, 20 ng/ml EGF, 0.24 % (w/v) agar (USB Corporation) and the respective EGFR inhibitor. Erlotinib was used at final concentrations of 2 μM and 3.2 μM, lapatinib at 4 μM and CI-1033 at 0.1 μM and 0.15 μM. For EGFR mutation screening in the ErbB2 background, erlotinib was applied at 2.5 μM, lapatinib at 4.5 μM and CI-1033 at 0.1 μM. Cells were incubated at 37
• C for 10-15 days to allow resistant colonies to develop. After isolation and expansion of drug-resistant colonies, genomic DNA was extracted using a Generation capture column kit (Gentra). The EGFR cytoplasmic domain was PCR amplified using forward (5 -CAACACCCTGGTCTGGAAGT-3 ) and reverse (5 -GGGTCCTACAGATCCTCTTCTG-3 ) primers and sequenced in both directions. Mutations were mapped on to the publicly available EGFR crystal structures to highlight potential mutations of particular interest and these were re-introduced into EGFRMyc-pBabe using the QuikChange ® mutagenesis kit (Strategene) to allow further functional characterization.
Cell-viability assay
Mixed populations of Ba/F3 cells expressing either wild-type EGFR or EGFR containing the desired point mutations were plated at 1 × The extent of cell proliferation was measured using a MTS (methanethiosulfonate)-based cell-viability assay (CellTiter96 Aqueous One Solution Reagent; Promega). The raw absorbance values were used to determine the concentration of drug required to inhibit 50 % of cell viability using the software package Origin (OriginLab). All IC 50 values presented are the means of at least two independent experiments.
Immunoblotting and immunoprecipitation
Cells (6 × 10 6 ) were lysed in buffer containing 25 mM Tris/HCl (pH 7.4), 150 mM NaCl, 0.27 M sucrose, 1 % (v/v) Triton X-100, 0.1 % (w/v) SDS, 3 mM EDTA, 3 mM EGTA, 10 mM β-glycerophosphate, 5 mM pyrophosphoate, 0.1 % (v/v) 2-mercaptoethanol, protease inhibitor cocktail (Roche), 2 mM sodium orthovanadate and 5 mM sodium fluoride, and were clarified by centrifugation at 10 000 g for 10 min at 4
• C. Proteins were separated by SDS/PAGE (4-20 % gels; Bio-Rad), transferred to Hybond-C Extra membrane (Amersham), blocked with TBST (Tris-buffered saline containing 0.1% Tween 20) containing 5 % (v/v) foetal calf serum, and probed with the relevant antibody. The antibodies used were: rabbit polyclonal anti-phospho-Tyr 1068 -EGFR (Biosource; used at 1:1000 dilution) and mouse monoclonal anti-Myc (clone 9E10; used at 1:1000 dilution) or rabbit polyclonal anti-phospho-Tyr 1248 -ErbB2 (Cell Signalling Technology; used at 1:1000 dilution) and anti-Myc antibodies (used at 1:1000 dilution). The anti-phospho-Tyr 1068 -EGFR antibody recognizes EGFR phosphorylated on Tyr 1068 of the mature human isoform 1 which corresponds to Tyr 1092 from the precursor form.
ErbB2 was immunoprecipitated from lysates prepared from 6 × 10 6 Ba/F3/ErbB2 or Ba/F3/EGFR+ErbB2 cells and incubated with 1.5 μg of anti-Myc antibody overnight at 4
• C, followed by incubation with Protein-G-Sepharose (Sigma-Aldrich) for 1 h. The immune complexes were probed with rabbit polyclonal phospho-Tyr 1248 -ErbB2 and anti-Myc antibodies. All immunoblots were probed with the respective secondary antibodies. Goat anti-rabbit IRDye800 (LI-COR Biosciences) was used at a 1:10000 dilution and goat anti-mouse IRDye680 (LI-COR Biosciences) was used at a 1:5000 dilution. Individual blots were scanned in the linear detection range using the Odyssey IR imaging system (LI-COR Biosciences) with both the 700 and 800 nm channels being captured in a single scan for each image. The signal changes in each image are therefore linear.
Computational tools
All protein structure diagrams were created using the Maestro package from Schrodinger.
RESULTS
Activation of EGFR and ErbB2 leads to IL-3-independent Ba/F3 cell growth
Previous reports demonstrated that expression of wild-type EGFR or activated EGFR-L858R in Ba/F3 cells is sufficient for IL-3-independent growth [6] . We therefore generated Ba/F3 cell lines stably expressing either wild-type EGFR, EGFR-L858R or ErbB2. To address whether ErbB2 can modulate the sensitivity of EGFR to inhibitors we also generated Ba/F3 lines co-expressing EGFR and ErbB2. Expression was verified by Western blotting (Figure 2a) , with only EGFR-L858R displaying detectable Tyr 1092 phosphorylation in the absence of EGF (Figures 2a and 2b ) confirming that this mutant is not dependent upon ligand. EGFR, EGFR and ErbB2, and EGFR-L858R cells all exhibited comparable levels of phospho-Tyr 1092 EGFR when exposed to EGF (Figure 2b ). Significant phospho-Tyr 1248 ErbB2 levels were observed in EGF-stimulated cells co-expressing EGFR and ErbB2 (Figure 2c ), whereas phosphorylated ErbB2 was also detected in Ba/F3/ErbB2 cells exposed to heregulin (Figure 2d ). ErbB3 mRNA has previously been detected in Ba/F3 cells [16] suggesting that low levels of ErbB3 protein are present and capable of activating ErbB2 in an heregulin-dependent manner. Ba/F3 cells expressing EGFR, EGFR and ErbB2, and ErbB2 proliferated at a similar rate in a ligand-dependent manner, whereas EGFR-L858R cells grew slightly faster irrespective of the presence of EGF (Figure 2e ). These results confirm previous reports that ErbB family members and mutants render Ba/F3 cells IL-3-independent and act as oncogenic stimuli [17] . Next we examined inhibition of EGFR signalling by erlotinib, lapatinib and CI-1033. Ba/F3 cells expressing ErbB family members were exposed to each inhibitor for 48 h before cell viability was assessed in order to determine the IC 50 of each inhibitor. For all EGFR-expressing cell lines the inhibitor potencies ranked in the following order: CI-1033>>erlotinib>lapatinib ( Table 1) . Introduction of L858R into EGFR led to a 10-15-fold increase in sensitivity to erlotinib and CI-1033, whereas lapatinib was unaffected (Table 1 ). Co-expression of EGFR with ErbB2 in the presence of EGF did not influence erlotinib or CI-1033 potency, but increased sensitivity to lapatinib 4-fold (Table 1 ). ErbB2 cells stimulated with heregulin were sensitive to both lapatinib and CI-1033 (Table1). Since each inhibitor was characterized using mixed populations of cells generated on several occasions, a degree of variation in the expression levels of each EGFR mutant was expected. The IC 50 s of the inhibitors were therefore measured on multiple occasions and the IC 50 values obtained were reproducible with at most a 2-fold variation being observed between individual experiments. This suggests that the expression levels of EGFR had little impact upon the IC 50 value obtained and supports the conclusion that the varying abilities of erlotinib, lapatinib and CI-1033 to inhibit EGFR-driven proliferation are due to their differing affinities for the various forms of EGFR.
EGFR resistance mutation screens with erlotinib, lapatinib and CI-1033
We used error-prone PCR to generate a library consisting of EGFR randomly mutated within its transmembrane, juxtamembrane and kinase domains. We focused upon these domains in order to specifically examine the direct structure-function relationship of the kinase domain with the various EGFR inhibitors. It is likely that by adopting this strategy we may have missed residues in the extracellular domain that could potentially cause drug resistance through indirect effects upon the conformation of the kinase domain.
We estimate that the library contained approx. 66000 clones with an approx. 1 bp change in each target sequence. Ba/F3 cells were infected with the EGFR mutation library and drug-resistant colonies were selected following previously published techniques [15] . The concentrations of erlotinib (2 and 3.2 μM), lapatinib (4 μM) and CI-1033 (0.1 and 0.15 μM) used in the screens were chosen to reflect the reported maximal drug plasma concentrations observed in the clinic [12, 18, 19] . Maximal concentrations of lapatinib were limited to 5 μM throughout the present study, since higher concentrations resulted in cell death of Ba/F3 cells (results not shown). To determine the impact of ErbB2 upon EGFR resistance, we also infected Ba/F3 cells stably expressing ErbB2 with the EGFR mutation library and selected for drug-resistant growth in the presence of erlotinib (2.5 μM), lapatinib (4.5 μM) and CI-1033 (0.1 μM).
Following each screen, resistant clones were picked, expanded and analysed by direct sequencing. Each inhibitor yielded differing proportions of mutated versus wild-type EGFRcontaining colonies in the various screens performed. Of the Cells were plated in triplicate at 1 × 10 5 cells per well and incubated with increasing concentrations of erlotinib (0-10 μM), lapatinib (0-5 μM) and CI-1033 (0-3 μM) for 48 h. Cells expressing EGFR-L858R were exposed to lower concentrations of erlotinib (0-3 μM) and CI-1033 (0-0.3 μM). Proliferation was measured using the MTS-based cell-viability assay. Growth curves and IC 50 values were generated using Origin 7.5 software. All IC 50 values are means of at least three independent experiments. ND, not determined. In total we discovered 40 mutated residues (Figure 3a) . Since crystal structures of EGFR complexed with erlotinib, lapatinib or 13-JAB (an irreversible inhibitor related to CI-1033) are available [9, 10] , we mapped mutations that were localized within drugcontact regions or specific functional regions of the kinase domain on to these crystal structures (Figures 3b-3d) . Erlotinib, lapatinib and CI-1033 all interact with the EGFR hinge region through the quinazoline ring, whereas the anilino group is orientated towards the selectivity pocket. The anilino group of lapatinib is extended when compared with erlotinib and CI-1033, resulting in it binding much deeper into the selectivity pocket. CI-1033 differs significantly from both erlotinib and lapatinib at the quinazoline 6-position where it contains a reactive group that forms a direct covalent bond with Cys 797 [20] . Mutation of the gatekeeper residue (T790M) was detected with varying frequencies in all six screens, although it was most prevalent with erlotinib ( Figure 3a and Supplementary Figure S1a at http://www.BiochemJ.org/bj/415/bj4150197add.htm). Mutations of Met 766 , Thr 854 , Leu 718 and Gly 796 were also identified in the erlotinib-resistance screen (Figure 3a) and each of these residues makes direct contact with erlotinib ( Figure 3b) . Interestingly, we also identified a number of erlotinib-resistant mutations (L777M, E762V/G, V769L, K852T/E and A859D) only in the presence of ErbB2 (Figure 3a) . In contrast, CI-1033 and lapatinib appeared less sensitive to the presence of ErbB2, presumably because they are both very efficient ErbB2 inhibitors. Lapatinib yielded the broadest mutation spectra of any of the inhibitors tested in our in vitro system (Figure 3a and Supplementary Figure S1b) . Some of the mutated residues (e.g. (Figure 3a) emphasizing the chemical similarities of the drug cores. However, there were a number of mutations (E709G, L747S, D770Y, H773L, C775F, R776P, L788I/V, K860T, G863S and R889S) that were unique to lapatinib (Figure 3a) . (Figure 3c ) suggesting that these regions may be particularly important for lapatinib binding. Comparison of the ratio of contact residues compared with non-contact residues for each inhibitor also suggested that binding of lapatinib significantly differed from both erlotinib and CI-1033. The majority (75 %) of residues mutated as a consequence of exposure to lapatinib did not directly contact ligand, whereas this frequency was dramatically lower with erlotinib (25 %) and CI-1033 (50 %).
Mapping of the CI-1033 resistance mutants on to the EGFR-13-JAB structure highlighted three interesting resistance clusters. The first cluster (C797S/G, G796R/C and P794L) was located near the solubilizing and reactive groups of CI-1033 (Figure 3d) . Cys 797 was the most frequently mutated residue identified in our CI-1033 screens (see Supplementary Figure S1c ). Cys 797 is critical for irreversible inhibitor binding [21] , since it contains the thiol group that reacts with CI-1033 to form the covalent bond. Gly 796 is positioned adjacent to the critical Cys 797 , whereas Pro 794 is located close to the morpholine group of CI-1033. The second mutation cluster (T790M and M766V/T) is located close to the aniline group of CI-1033 (Figure 3d) . Interestingly, the T790M mutation was significantly less prevalent in the CI-1033 screen when compared with the erlotinib screen (Supplementary Figure S1c) . The final cluster observed (V742A, A743S and I744F) was located above the quinazoline ring of CI-1033 (Figure 3d ).
The impact of EGFR mutations upon drug sensitivity
Having mapped the resistance mutations obtained in our screens we sought to determine the degree of resistance conferred by selected mutations to erlotinib, lapatinib and CI-1033. Mutations T790M (gatekeeper), M766T (C-helix), L718A (solvent chanel) and T854A (activation loop) were most prevalent in the erlotinib screen, whereas mutations G796R and C797S (solvent chanel) were most frequently detected in the CI-1033 screen (Supplementary Figures S1a and S1c). We introduced these EGFR variants into Ba/F3 cells for further testing of drug resistance. We also chose H773L, R776P, L777Q and L788V mutations, since they were identified only in the lapatinib screen. In addition, we took advantage of the fact that co-expression of ErbB2 markedly lowered the IC 50 of lapatinib in order to overcome the limitations imposed by its cellular toxicity. All cell lines were treated with increasing doses of erlotinib, lapatinib and CI-1033 to generate cell proliferation dose-response curves. As expected, EGFR-T790M was highly resistant to erlotinib and lapatinib ( Figure S2c) . The effect of M766T, L718A and T854A upon erlotinib and CI-1033 potency was much more moderate with only a 3-8-fold IC 50 increase being observed (Table 2 and Supplementary Figures S2a and S2c). L718A and T854A conferred resistance to lapatinib, whereas M766T slightly sensitized EGFR to lapatinib (Table 2 and Supplementary Figure S2b) . G796R increased resistance to CI-1033 100-fold, supporting the significance of this residue in the covalent bond formed by the adjacent Cys 797 (Table 2 and Supplementary Figure S2c) . Mutation of Gly 796 was also detected in the erlotinib screen and decreased the potency of both lapatinib and erlotinib (Table 2 and Supplementary Figures S2a and S2b), indicating that this residue adversely affects groups on the 6/7 positions of the quinazoline ring. As expected, the C797S mutation severely affected CI-1033 binding resulting in an approx. 170-fold increase in the growth IC 50 (Table 2 and Supplementary Figure S3c at http://www.BiochemJ.org/bj/415/ bj4150197add.htm). Co-expression of ErbB2 with EGFR-H773L, -R776P, -L777Q and -L788V displayed complete resistance to lapatinib (Table 3 and Supplementary Figure S4b at http://www.BiochemJ.org/bj/ 415/bj4150197add.htm), thus substantiating the importance of the selectivity pocket for lapatinib binding. Furthermore, lapatinib treatment of Ba/F3 cells co-expressing EGFR-L788V and ErbB2 failed to completely inhibit EGFR Tyr 1092 phosphorylation at concentrations 6-fold higher than the wild-type IC 50 (Figure 4) , thus confirming the inability of lapatinib to directly inhibit these selectivity pocket mutants.
The relationship between L858R and drug-resistant mutants
To assess the potential clinical impact of T790M, M766T, L718A, T854A, G796R and C797S upon drug sensitivity, these mutations were introduced into the clinically relevant EGFR-L858R background. In addition, we also generated EGFR-T790M-C797S-L858R to investigate how the combination of the two most prevalent erlotinib and CI-1033 resistance mutations affected drug sensitivity. The overall pattern of resistance conferred by T790M was similar in both the wild-type EGFR and L858R background (Tables 2 and 4 in our proliferation assays ( Figure 4 and Table 4) confirming that drug resistance was primarily driven by the EGFR mutation. A similarly decreased sensitivity to irreversible inhibitors was also recently reported with EGFR-L858R-T790M treated with HKI-272 [21] .
Combination of either M766T or G796R with L858R severely affected cell proliferation (results not shown) indicating that 
(μM) and fold-change of EGFR-L858R mutations
Cells expressing EGFR-L858R proteins with indicated resistance mutations were incubated with increasing concentrations of erlotinib (0-10 μM), lapatinib (0-5 μM) and CI-1033 (0-3 μM) for 48 h. EGFR-L858R cells were treated with erlotinib at 0-3 μM, lapatinib at 0-5 μM and CI-1033 at 0-0.3 μM for 48 h. Proliferation was measured and IC 50 values (μM) were generated as described in Table 1 . All values are means of at least two independent experiments. The fold-change in IC 50 values compared with L858R are indicated in parentheses. For L858R+M766T the cell viability was impaired. For L858R+G796R the cells were not viable. E, erlotinib; L, lapatinib; C, CI-1033.
Mutation
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both mutations, when combined with L858R, impaired EGFR activity. Although resistance to erlotinib and CI-1033 was observed with EGFR-L858R-M766T, this mutant surprisingly sensitized EGFR to lapatinib (Table 4 and Supplementary Figure  S3 ). L858R-L718A conferred significant resistance to erlotinib (17.3-fold increase) and CI-1033 (11.2-fold increase), whereas L858R-T854A demonstrated less resistance to all tested inhibitors when compared with L858R-L718A (Table 4 and Supplementary  Figures S3a-S3c ). Similar to wild-type EGFR, the introduction of C797S into L858R dramatically impaired EGFR inhibition by CI-1033 as assessed by both proliferation and Tyr 1092 phosphorylation (Table 4 and Figure 4) . Complete resistance to all inhibitors at the maximum tolerated doses was achieved when T790M and C797S mutations were combined in the L858R mutation background (Table 4) demonstrating how results from these screens can be used to predict structure-function relationships.
The impact of ErbB2 upon EGFR drug resistance
Since E762V, V769L and K852T mutations were detected in the erlotinib screen performed in the presence of ErbB2, we examined the relationship between these mutations and ErbB2.
To evaluate their effect we expressed and characterized EGFR-E762V, -V769L and -K852T in the presence or absence of ErbB2. Ba/F3 cells infected with EGFR-E762V did not survive in IL-3-free medium supplemented with EGF, suggesting that activation of EGFR was severely impaired by mutation of this important residue. Unexpectedly, co-expression of ErbB2 with EGFR-E762V resulted in viable cells that were mildly resistant to erlotinib and significantly more sensitive to lapatinib (Table 3 and Supplementary Figures S4a and S4b) . Co-expression of ErbB2 with EGFR-V769L consistently increased the level of resistance observed with erlotinib, lapatinib and CI-1033 (Tables 2 and 3 , and Figure 4b ). EGFR-K852T conferred mild resistance to erlotinib (Table 2) , but much more significant increases in erlotinib, lapatinib and CI-1033 resistance (5-8-fold) were observed when K852T was co-expressed with ErbB2 (Table 3 and Supplementary  Figures S4a-S4c ). This increased resistance was consistent with K852T only being identified in screens where ErbB2 was present. 
Combination of erlotinib and CI-1033 significantly reduces drug-resistant colony formation
We established that the key erlotinib-resistance mutation is T790M, whereas mutations of C797S and G796R strongly impaired inhibition by CI-1033. We predicted that combination of erlotinib and CI-1033 should significantly reduce the number of resistant clones, since proliferation of cells expressing EGFR-T790M was potently inhibited by CI-1033, whereas erlotinib efficiently inhibited C797S. The resistance screen was therefore repeated in the presence of various concentrations of erlotinib and CI-1033. We observed that increasing concentrations of either erlotinib or CI-1033 inversely correlated with the number of resistant colonies obtained ( Figure 5 ). As predicted, the combination of erlotinib with CI-1033 was extremely effective in preventing the formation of resistant colonies, presumably because each inhibitor exerts selective pressure in a complementary manner ( Figure 5 ).
DISCUSSION
The present study of EGFR drug-resistant mutations demonstrates that erlotinib, lapatinib and CI-1033 each yield a different mutational profile despite the overall similarity in their chemical structures. For erlotinib, the primary resistance hotspot is observed at the entrance to the selectivity pocket, whereas lapatinibresistant mutations were clustered deep in the selectivity pocket and on the activation loop. CI-1033 was exquisitely sensitive to mutations on and around Cys 797 , where the covalent bond is formed. T790M was the only mutation consistently identified in all of our screens, thus confirming the importance of the gatekeeper residue in drug resistance. The exact mechanism through which T790M blocks drug binding is not completely understood, though steric interference caused by the bulkier methionine residue is thought to contribute [22] . The importance of the selectivity pocket in determining erlotinib binding is emphasized by the prevalence of Met 766 and Thr 854 mutations in our resistance screens. Met 766 forms part of the pocket in which the anilino group of erlotinib binds and substitution by the hydrophilic threonine residue would probably affect the electrostatic nature of the pocket, whereas substitution with a valine residue may affect the shape of the pocket. Furthermore, M766T/V is particularly interesting, since it resides on the C-helix of EGFR suggesting that it may additionally influence the equilibrium between C-helix 'in' and 'out' conformations, thus differentially affecting the binding affinity for either ATP or erlotinib. Mutation of Thr 854 to the smaller, hydrophobic alanine residue may increase the size of the selectivity pocket, thus negatively impacting erlotinib binding.
Although our studies with lapatinib were limited by its cellular toxicity, it consistently yielded a broader spectrum of mutations than CI-1033 or erlotinib. Many of the most prevalent lapatinibresistant mutations clustered in and around the EGFR selectivity pocket highlighting the importance of this region for binding of kinase inhibitors with extended aniline groups. This finding is exemplified by Leu 747 and Arg 776 , which localize deep in the selectivity pocket. Similar to erlotinib and CI-1033, residues such as Cys 775 , Leu 777 and Leu 788 that directly contact ligand are prone to mutation as an escape mechanism. For example, Cys 775 substitution with the bulkier phenylalanine residue may cause a steric clash with the aniline group and L777Q mutation involves replacement of a hydrophobic residue with a hydrophilic one, thereby reducing the potency of lapatinib, since the binding of the anilino group appears principally driven through hydrophobic interactions.
Upon close examination of the overall proportion of contact compared with non-contact residues combined with the location of each mutation we noticed that mutations that affect the conformation of EGFR might offer an additional resistance mechanism to lapatinib. This mechanism appears unique to lapatinib (when compared with erlotinib and CI-1033) and is suggested by the low frequency (25 %) of mutated contact residues ( Figure 3A) and their structural location. For instance, mutations preceding the EGFR C-helix (e.g. D770Y, R776P and H773L) may influence the conformation state of EGFR and thus prevent lapatinib binding. For example, the H773L mutation may favour the C-helix 'in' confirmation consequently disfavouring lapatinib binding, whereas activation-loop mutations (e.g. T854S, K860T, G863S and R889S) may also influence the C-helix 'in'/'out' conformational equilibrium, as studies with Abl indicate that the movements of the activation loop and C-helix might be correlated [23] .
Our discovery that lapatinib consistently generated a broad mutation spectrum is analogous to that demonstrated with imatinib [24] . This similarity supports the finding that inhibitors that make extensive use of the selectivity pocket (e.g. lapatinib) and preferentially bind to an inactive conformation are more vulnerable to resistance mutations. This highlights an apparent conflict in the design of kinase inhibitors, since approaches to gain maximum kinase selectivity usually involve interacting with residues distal from the ATP-binding site within the selectivity pocket. This situation is perhaps best illustrated by comparing imatinib with the Aurora kinase inhibitor VX-680 [25] . VX-680 does not significantly interact with the selectivity pocket and is therefore able to overcome a number of BCR-Abl mutations including T315I [25] . However, since it interacts with residues that are in contact with ATP, its kinase selectivity profile is much broader than that of imatinib [5] .
Resistance to CI-1033 was dominated by mutation of residues located near the solubilizing and reactive groups of CI-1033. CI-1033 was exquisitely sensitive to the C797S mutation, since Cys 797 is critical for irreversible inhibitor binding. Although serine contains an hydroxy side chain that is potentially available for covalent reaction, serine is much less chemically reactive when compared with cysteine. Mutations or residues around Cys 797 (e.g. G796R/C and P794L) may also interfere with the ability of CI-1033 to form covalent interactions by affecting the conformation and/or accessibility of the key Cys 797 residue.
In the present study we frequently observed C797S and G796R/C mutations and confirmed that they are the key mutations involved in CI-1033 resistance. In contrast with our findings, a study by Yu et al. [26] did not identify the Cys 797 mutation in L858R-T790M-mutant lung adenocarcinoma cells adapted for resistance to the irreversible inhibitor CL-387,785. In addition, cells engineered by Yu et al. [26] to express EGFR-T790M-L858R-C797S conferred only mild resistance to CL-387,785. There are several explanations for these differences. One possibility is simply that CI-1033 and CL-387,785 are structurally distinct and may therefore behave differently in a cellular environment. Alternatively, since our results suggest that the presence of EGFR-binding partners (e.g. ErbB2) can modulate the resistance spectrum by either promoting the survival of a drugresistant mutant (e.g. EGFR-E762V) or rendering a particular mutant markedly more drug resistant (e.g. EGFR-K852T) it is conceivable that the interacting proteins present in the cell lines used in the screens differed sufficiently to influence both the resistance mutation profile and the degree of resistance obtained.
Several of the hypotheses that we have proposed for the mechanisms by which the various mutations confer drug resistance are speculative predictions based upon structural models or previous findings with BCR-Abl. It is possible that other explanations exist to rationalize our findings. For example, increased expression of BCR-Abl results in imatinib resistance [27] . Perhaps some of our resistance mutations could stabilize EGFR, resulting in increased protein levels and resistance to the various inhibitors tested. Definitive proof of the precise mechanisms underlying drug resistance will require a variety of cellular, biochemical and crystallographic techniques to study each mutation in further detail, and we await the outcomes of these studies with interest.
Numerous ErbB family irreversible inhibitors are currently being investigated as a method to overcome clinical resistance driven by the T790M mutation of EGFR [28] . Our screening data with the irreversible inhibitor CI-1033 indicates that clinical resistance to this class of inhibitor is possible and we expect that incidences of EGFR-Gly 796 and -Cys 797 mutations will be reported in the clinic following prolonged exposure to irreversible inhibitors. Interestingly, alignment of the ErbB2 and EGFR kinase domains indicates that many of the lapatinib-and CI-1033-resistance residues are conserved in ErbB2 (Supplementary Figure S4 ). This suggests that clinical resistance (either acquired or intrinsic) due to ErbB2 mutations is a likely possibility in ErbB2-driven tumours treated with either lapatinib or irreversible inhibitors. Based upon the present study, we predict that ErbB2-Cys 805 will be observed in response to irreversible inhibitors, whereas lapatinib will yield a broad range of mutations that will probably include the gatekeeper (ErbB2-Thr 798 ) and residues clustered deep in the selectivity pocket.
Combinations of drugs that bind to different conformations of BCR-Abl have been demonstrated preclinically to be an effective method of reducing the frequency of resistance mutations [24, 29] . Our in vitro data suggest that if the toxicity could be tolerated then a combination of erlotinib/gefitinib and an irreversible inhibitor in first-line therapy might be a useful approach to prevent expansion of resistant clones harbouring T790M or C797S mutations. However, if T790M and C797S were mutated in the same EGFR allele then complete resistance to current EGFR kinase inhibitors would probably occur. If EGFR-driven NSCLC behaves similarly to BCR-Abl-driven CML then the chances of acquiring multiple resistance mutations in the same EGFR allele would probably be heightened if the EGFR-targeted therapies were applied in a sequential manner. This scenario has very recently been observed in CML patients treated with imatinib, dasatinib and nilotinib [30] [31] [32] . It is probable that the outcome of future combination trials in resistant disease will determine whether the combination of targeted therapies that inhibit distinct molecular targets will unlock their full potential to deliver significant patient benefit.
Figure S2 Drug sensitivity of EGFR mutants
The relative degree of resistance to (a) erlotinib, (b) lapatinib and (c) CI-1033 imparted by mutated residues was plotted on to the EGFR crystal structures. The highlighted amino acids are represented as ball and stick structures. EGFR resistance mutations are colour-coded depending upon the degree of resistance conferred when tested in a cell-viability assay. Colours represent the fold-change in IC 50 when compared with wild-type EGFR-expressing Ba/F3 cells. Green represents sensitizing mutations, white represents no significant change in IC 50 , shades of red represent increasing levels of resistance and dark red represents no observable inhibition at the maximal drug concentration (over-range). Comparison of EGFR resistance mutation spectra
Figure S4 The impact of ErbB2 upon sensitivity of EGFR mutations to inhibitors
The degree of resistance to (a) erlotinib, (b) lapatinib and (c) CI-1033 imparted by EGFR mutations expressed in the presence of ErbB2 were mapped on to EGFR-erlotinib, EGFR-lapatinib and EGFR-13-JAB structures. The degree of resistance was colour coded as described in the legend to Figure S2 . 
